Advertisement

Cancer and Metastasis Reviews

, Volume 32, Issue 1–2, pp 303–315 | Cite as

Stromal cells in tumor microenvironment and breast cancer

  • Yan Mao
  • Evan T. Keller
  • David H. Garfield
  • Kunwei ShenEmail author
  • Jianhua WangEmail author
NON-THEMATIC REVIEW

Abstract

Cancer is a systemic disease encompassing multiple components of both tumor cells themselves and host stromal cells. It is now clear that stromal cells in the tumor microenvironment play an important role in cancer development. Molecular events through which reactive stromal cells affect cancer cells can be defined so that biomarkers and therapeutic targets can be identified. Cancer-associated fibroblasts (CAFs) make up the bulk of cancer stroma and affect the tumor microenvironment such that they promote cancer initiation, angiogenesis, invasion, and metastasis. In breast cancer, CAFs not only promote tumor progression but also induce therapeutic resistance. Accordingly, targeting CAFs provides a novel way to control tumors with therapeutic resistance. This review summarizes the current understandings of tumor stroma in breast cancer with a particular emphasis on the role of CAFs and the therapeutic implications of CAFs. In addition, the effects of other stromal components such as endothelial cells, macrophages, and adipocytes in breast cancer are also discussed. Finally, we describe the biologic markers to categorize patients into a specific and confirmed subtype for personalized treatment.

Keywords

Stromal cells Tumor microenvironment Cancer-associated fibroblasts (CAFs) Breast cancer 

Notes

Acknowledgments

We apologize to the many authors whose excellent work we could not cite owing to space limitation. Research in the authors’ laboratory is supported by National Natural funding of China (81272404, 81071747, 81202087, 81172520), National Key Program (973) for Basic Research of China (2011CB510106, 2011CB504300), Shanghai Education Committee Key Discipline and Specialties Foundation (J50208), the Program for Professor of Special Appointment (Eastern Scholar to J. Wang) at Shanghai Institutions of Higher Learning, and Shanghai Pujiang Program (10PJ1406400), Shanghai Committee of Science and Technology (11DZ2260200), and the Program of Shanghai Municipal Health Bureau Subject Chief Scientist (XBR20110052), National Institutes of Health grant P01 CA093900. This research was supported in part by the grants from Leading Academic Discipline Project of Shanghai Municipal Education Commission (Grant Number: J50208); National Natural Science Foundation of China (Grant Number: 81202087; 81172520).

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Siegel, R., et al. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10–29.CrossRefGoogle Scholar
  2. 2.
    Paget, S. (1989). The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Reviews, 8(2), 98–101.PubMedGoogle Scholar
  3. 3.
    Kalluri, R., et al. (2006). Fibroblasts in cancer. Nature Reviews. Cancer, 6(5), 392–401.PubMedCrossRefGoogle Scholar
  4. 4.
    Ostman, A., et al. (2009). Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Current Opinion in Genetics and Development, 19(1), 67–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Loeffler, M., et al. (2006). Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. The Journal of Clinical Investigation, 116(7), 1955–1962.PubMedCrossRefGoogle Scholar
  6. 6.
    Gabbiani, G., et al. (1971). Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia, 27(5), 549–550.PubMedCrossRefGoogle Scholar
  7. 7.
    Dvorak, H. F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine, 315(26), 1650–1659.PubMedCrossRefGoogle Scholar
  8. 8.
    Kojima, Y., et al. (2010). Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 107(46), 20009–20014.PubMedCrossRefGoogle Scholar
  9. 9.
    Moskovits, N., et al. (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Research, 66(22), 10671–10676.PubMedCrossRefGoogle Scholar
  10. 10.
    Aboussekhra, A. (2011). Role of cancer-associated fibroblasts in breast cancer development and prognosis. International Journal of Developmental Biology, 55(7–9), 841–849.PubMedCrossRefGoogle Scholar
  11. 11.
    Kiaris, H., et al. (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Research, 65(5), 1627–1630.PubMedCrossRefGoogle Scholar
  12. 12.
    Trimis, G., et al. (2008). Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Human Molecular Genetics, 17(22), 3596–3600.PubMedCrossRefGoogle Scholar
  13. 13.
    Trimboli, A. J., et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature, 461(7267), 1084–1091.PubMedCrossRefGoogle Scholar
  14. 14.
    Trimmer, C., et al. (2011). Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biology & Therapy, 11(4), 383–394.CrossRefGoogle Scholar
  15. 15.
    Hill, R., et al. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell, 123(6), 1001–1011.PubMedCrossRefGoogle Scholar
  16. 16.
    Spaeth, E. L., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One, 4(4), e4992.PubMedCrossRefGoogle Scholar
  17. 17.
    Jotzu, C., et al. (2010). Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Analytical Cellular Pathology (Amsterdam), 33(2), 61–79.Google Scholar
  18. 18.
    Zeisberg, E. M., et al. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123–10128.PubMedCrossRefGoogle Scholar
  19. 19.
    Garin-Chesa, P., et al. (1990). Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proceedings of the National Academy of Sciences of the United States of America, 87(18), 7235–7239.PubMedCrossRefGoogle Scholar
  20. 20.
    Erez, N., et al. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135–147.PubMedCrossRefGoogle Scholar
  21. 21.
    Mercier, I., et al. (2008). Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biology & Therapy, 7(8), 1212–1225.CrossRefGoogle Scholar
  22. 22.
    Sugimoto, H., et al. (2006). Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biology & Therapy, 5(12), 1640–1646.CrossRefGoogle Scholar
  23. 23.
    Perou, C. M., et al. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752.PubMedCrossRefGoogle Scholar
  24. 24.
    Haque, R., et al. (2012). PS1-05: disparities in breast cancer survival by molecular subtype and race/ethnicity. Clinical Medicine & Research, 10(3), 145.CrossRefGoogle Scholar
  25. 25.
    Onitilo, A. A., et al. (2009). Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical Medicine & Research, 7(1–2), 4–13.CrossRefGoogle Scholar
  26. 26.
    Martinez-Outschoorn, U. E., et al. (2010). Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 9(12), 2423–2433.PubMedCrossRefGoogle Scholar
  27. 27.
    Lohr, M., et al. (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Research, 61(2), 550–555.PubMedGoogle Scholar
  28. 28.
    Bronzert, D. A., et al. (1987). Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proceedings of the National Academy of Sciences of the United States of America, 84(16), 5763–5767.PubMedCrossRefGoogle Scholar
  29. 29.
    Shao, Z. M., et al. (2000). Human breast carcinoma desmoplasia is PDGF initiated. Oncogene, 19(38), 4337–4345.PubMedCrossRefGoogle Scholar
  30. 30.
    Strutz, F., et al. (2000). Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney International, 57(4), 1521–1538.PubMedCrossRefGoogle Scholar
  31. 31.
    Giannoni, E., et al. (2010). Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial–mesenchymal transition and cancer stemness. Cancer Research, 70(17), 6945–6956.PubMedCrossRefGoogle Scholar
  32. 32.
    Hugo, H. J., et al. (2012). Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenvironment. doi: 10.1007/s12307-012-0098-7
  33. 33.
    Koleske, A. J., et al. (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 92(5), 1381–1385.PubMedCrossRefGoogle Scholar
  34. 34.
    Martinez-Outschoorn, U. E., et al. (2010). Oxidative stress in cancer associated fibroblasts drives tumor–stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle, 9(16), 3256–3276.PubMedCrossRefGoogle Scholar
  35. 35.
    Al-Ansari, M. M., et al. (2012). p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene. doi:10.1038/onc.2012.270
  36. 36.
    Serrano, M., et al. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366(6456), 704–707.PubMedCrossRefGoogle Scholar
  37. 37.
    Ohtani, N., et al. (2004). The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. The Journal of Medical Investigation, 51(3–4), 146–153.PubMedCrossRefGoogle Scholar
  38. 38.
    Matros, E., et al. (2005). BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Research and Treatment, 91(2), 179–186.PubMedCrossRefGoogle Scholar
  39. 39.
    Hasebe, T., et al. (2001). Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Modern Pathology, 14(4), 325–337.PubMedCrossRefGoogle Scholar
  40. 40.
    Orimo, A., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335–348.PubMedCrossRefGoogle Scholar
  41. 41.
    Saito, R. A., et al. (2010). Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Research, 70(7), 2644–2654.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhang, C., et al. (2009). Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clinical Cancer Research, 15(12), 4017–4027.PubMedCrossRefGoogle Scholar
  43. 43.
    Shekhar, M. P., et al. (2001). Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Research, 61(4), 1320–1326.PubMedGoogle Scholar
  44. 44.
    Sadlonova, A., et al. (2005). Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Research, 7(1), R46–R59.PubMedCrossRefGoogle Scholar
  45. 45.
    Adams, E. F., et al. (1988). Effects of human breast fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of MCF-7 cells in culture. Breast Cancer Research and Treatment, 11(2), 165–172.PubMedCrossRefGoogle Scholar
  46. 46.
    Stuelten, C. H., et al. (2010). Transient tumor–fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One, 5(3), e9832.PubMedCrossRefGoogle Scholar
  47. 47.
    Hu, M., et al. (2009). Role of COX-2 in epithelial–stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3372–3377.PubMedCrossRefGoogle Scholar
  48. 48.
    Hu, M., et al. (2008). Regulation of in situ to invasive breast carcinoma transition. Cancer Cell, 13(5), 394–406.PubMedCrossRefGoogle Scholar
  49. 49.
    Tsuyada, A., et al. (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Research, 72(11), 2768–2779.PubMedCrossRefGoogle Scholar
  50. 50.
    Qian, B. Z., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222–225.PubMedCrossRefGoogle Scholar
  51. 51.
    Tan, W., et al. (2011). Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature, 470(7335), 548–553.PubMedCrossRefGoogle Scholar
  52. 52.
    Rossi, D., et al. (2000). The biology of chemokines and their receptors. Annual Review of Immunology, 18, 217–242.PubMedCrossRefGoogle Scholar
  53. 53.
    Roodman, G. D. (2004). Mechanisms of bone metastasis. The New England Journal of Medicine, 350(16), 1655–1664.PubMedCrossRefGoogle Scholar
  54. 54.
    Azim, H. A., et al. (2012). Bone metastasis in breast cancer: the story of RANK-ligand. Journal of the Egyptian National Cancer Institute, 24(3), 107–114.PubMedCrossRefGoogle Scholar
  55. 55.
    Chen, J., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell, 19(4), 541–555.PubMedCrossRefGoogle Scholar
  56. 56.
    Campbell, I., et al. (2009). Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Research, 69(17), 6765–6768. discussion 6769.PubMedCrossRefGoogle Scholar
  57. 57.
    Hu, M., et al. (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genetics, 37(8), 899–905.PubMedCrossRefGoogle Scholar
  58. 58.
    Allinen, M., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6(1), 17–32.PubMedCrossRefGoogle Scholar
  59. 59.
    Enkelmann, A., et al. (2011). Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. Journal of Cancer Research and Clinical Oncology, 137(5), 751–759.PubMedCrossRefGoogle Scholar
  60. 60.
    Fiegl, H., et al. (2006). Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Research, 66(1), 29–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Jiang, L., et al. (2008). Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Research, 68(23), 9900–9908.PubMedCrossRefGoogle Scholar
  62. 62.
    Yu, J., et al. (2012). Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2′-deoxycytidine. PLoS One, 7(9), e43456.PubMedCrossRefGoogle Scholar
  63. 63.
    Robinson, C. M., et al. (2012). Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respiratory Research, 13(1), 74.PubMedCrossRefGoogle Scholar
  64. 64.
    Knower, K. C., et al. (2010). Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. Molecular and Cellular Endocrinology, 321(2), 123–130.PubMedCrossRefGoogle Scholar
  65. 65.
    Tyan, S. W., et al. (2012). Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS One, 7(4), e35128.PubMedCrossRefGoogle Scholar
  66. 66.
    Gangaraju, V. K., et al. (2009). MicroRNAs: key regulators of stem cells. Nature Reviews Molecular Cell Biology, 10(2), 116–125.PubMedCrossRefGoogle Scholar
  67. 67.
    Fazi, F., et al. (2008). MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. Cardiovascular Research, 79(4), 553–561.PubMedCrossRefGoogle Scholar
  68. 68.
    Leung, A. K., et al. (2006). Function and localization of microRNAs in mammalian cells. Cold Spring Harbor Symposia on Quantitative Biology, 71, 29–38.PubMedCrossRefGoogle Scholar
  69. 69.
    Tiscornia, G., et al. (2010). MicroRNAs in embryonic stem cell function and fate. Genes & Development, 24(24), 2732–2741.CrossRefGoogle Scholar
  70. 70.
    Davis-Dusenbery, B. N., et al. (2010). MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer, 1(11), 1100–1114.PubMedCrossRefGoogle Scholar
  71. 71.
    Farazi, T. A., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Research, 71(13), 4443–4453.PubMedCrossRefGoogle Scholar
  72. 72.
    Iliopoulos, D., et al. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139(4), 693–706.PubMedCrossRefGoogle Scholar
  73. 73.
    Iliopoulos, D., et al. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Molecular Cell, 39(4), 493–506.PubMedCrossRefGoogle Scholar
  74. 74.
    Iorio, M. V., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.PubMedCrossRefGoogle Scholar
  75. 75.
    Jazbutyte, V., et al. (2010). MicroRNA-21: from cancer to cardiovascular disease. Current Drug Targets, 11(8), 926–935.PubMedCrossRefGoogle Scholar
  76. 76.
    Qian, B., et al. (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Research and Treatment, 117(1), 131–140.PubMedCrossRefGoogle Scholar
  77. 77.
    Aprelikova, O., et al. (2012). Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene. doi:10.1038/onc.2012.351
  78. 78.
    Aprelikova, O., et al. (2010). The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle, 9(21), 4387–4398.PubMedCrossRefGoogle Scholar
  79. 79.
    Musumeci, M., et al. (2010). Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 30(41), 4231–4242.CrossRefGoogle Scholar
  80. 80.
    Martinez-Outschoorn, U. E., et al. (2011). Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology & Therapy, 12(10), 924–938.CrossRefGoogle Scholar
  81. 81.
    Sun, Y., et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine. doi:10.1038/nm.2890
  82. 82.
    Tchou, J., et al. (2012). Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Advances in Pharmacology, 65, 45–61.PubMedCrossRefGoogle Scholar
  83. 83.
    Davies, C., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784.PubMedGoogle Scholar
  84. 84.
    Shekhar, M. P., et al. (2007). Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. American Journal of Pathology, 170(5), 1546–1560.PubMedCrossRefGoogle Scholar
  85. 85.
    Pontiggia, O., et al. (2012). The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. Breast Cancer Research and Treatment, 133(2), 459–471.PubMedCrossRefGoogle Scholar
  86. 86.
    Mueller, K. L., et al. (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Research, 14(4), R104.PubMedCrossRefGoogle Scholar
  87. 87.
    Johansson, A. C., et al. (2012). Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Molecular Cancer Research, 10(9), 1158–1168.PubMedCrossRefGoogle Scholar
  88. 88.
    Dittmer, A., et al. (2011). Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors. International Journal of Oncology, 39(3), 689–696.PubMedGoogle Scholar
  89. 89.
    Capparelli, C., et al. (2012). CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle, 11(19).Google Scholar
  90. 90.
    Bergamaschi, A., et al. (2008). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of Pathology, 214(3), 357–367.PubMedCrossRefGoogle Scholar
  91. 91.
    Finak, G., et al. (2008). Stromal gene expression predicts clinical outcome in breast cancer. Nature Medicine, 14(5), 518–527.PubMedCrossRefGoogle Scholar
  92. 92.
    Sloan, E. K., et al. (2009). Stromal cell expression of caveolin-1 predicts outcome in breast cancer. American Journal of Pathology, 174(6), 2035–2043.PubMedCrossRefGoogle Scholar
  93. 93.
    Pavlides, S., et al. (2009). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle, 8(23), 3984–4001.PubMedCrossRefGoogle Scholar
  94. 94.
    Farmer, P., et al. (2009). A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15(1), 68–74.PubMedCrossRefGoogle Scholar
  95. 95.
    Ahn, S., et al. (2012). The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biology, 33, 1573–1580.Google Scholar
  96. 96.
    Martinet, L., et al. (2011). Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Research, 71(17), 5678–5687.PubMedCrossRefGoogle Scholar
  97. 97.
    DeNardo, D. G., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67.PubMedCrossRefGoogle Scholar
  98. 98.
    Laoui, D., et al. (2011). Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. International Journal of Developmental Biology, 55(7–9), 861–867.PubMedCrossRefGoogle Scholar
  99. 99.
    Lee, A. H., et al. (1997). Angiogenesis and inflammation in invasive carcinoma of the breast. Journal of Clinical Pathology, 50(8), 669–673.PubMedCrossRefGoogle Scholar
  100. 100.
    Campbell, M. J., et al. (2011). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Research and Treatment, 128(3), 703–711.PubMedCrossRefGoogle Scholar
  101. 101.
    Leek, R. D., et al. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Research, 56(20), 4625–4629.PubMedGoogle Scholar
  102. 102.
    Lewis, C. E., et al. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605–612.PubMedCrossRefGoogle Scholar
  103. 103.
    Lewis, J. S., et al. (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. The Journal of Pathology, 192(2), 150–158.PubMedCrossRefGoogle Scholar
  104. 104.
    Dirkx, A. E., et al. (2006). Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. Journal of Leukocyte Biology, 80(6), 1183–1196.PubMedCrossRefGoogle Scholar
  105. 105.
    Roland, C. L., et al. (2009). Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 8(7), 1761–1771.PubMedCrossRefGoogle Scholar
  106. 106.
    Melani, C., et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438–11446.PubMedCrossRefGoogle Scholar
  107. 107.
    Lin, E. Y., et al. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine, 193(6), 727–740.PubMedCrossRefGoogle Scholar
  108. 108.
    Oosterling, S. J., et al. (2005). Macrophages direct tumour histology and clinical outcome in a colon cancer model. The Journal of Pathology, 207(2), 147–155.PubMedCrossRefGoogle Scholar
  109. 109.
    Mukhtar, R. A., et al. (2011). Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Review of Molecular Diagnostics, 11(1), 91–100.PubMedCrossRefGoogle Scholar
  110. 110.
    Nilsson, S., et al. (2012). Downregulation of miR-92a is associated with aggressive breast cancer features and increased tumour macrophage infiltration. PLoS One, 7(4), e36051.PubMedCrossRefGoogle Scholar
  111. 111.
    Yang, M., et al. (2011). Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular Cancer, 10, 117.PubMedCrossRefGoogle Scholar
  112. 112.
    Hiraoka, K., et al. (2008). Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science, 99(8), 1595–1602.PubMedCrossRefGoogle Scholar
  113. 113.
    Gazzaniga, S., et al. (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. The Journal of Investigative Dermatology, 127(8), 2031–2041.PubMedCrossRefGoogle Scholar
  114. 114.
    Zeisberger, S. M., et al. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3), 272–281.PubMedCrossRefGoogle Scholar
  115. 115.
    Zhang, W., et al. (2010). Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research, 16(13), 3420–3430.PubMedCrossRefGoogle Scholar
  116. 116.
    Veltman, J. D., et al. (2010). Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. British Journal of Cancer, 103(5), 629–641.PubMedCrossRefGoogle Scholar
  117. 117.
    Luckman, S. P., et al. (1998). Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. Journal of Bone and Mineral Research, 13(11), 1668–1678.PubMedCrossRefGoogle Scholar
  118. 118.
    Cecchini, M. G., et al. (1987). Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. Journal of Bone and Mineral Research, 2(2), 135–142.PubMedCrossRefGoogle Scholar
  119. 119.
    Coscia, M., et al. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 14(12), 2803–2815.PubMedCrossRefGoogle Scholar
  120. 120.
    Man, Y. G., et al. (2004). The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the “protease-centered” hypothesis. Experimental Cell Research, 301(2), 103–118.PubMedCrossRefGoogle Scholar
  121. 121.
    Knutson, K. L., et al. (2006). IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology, 177(1), 84–91.Google Scholar
  122. 122.
    Mahmoud, S. M., et al. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology, 29(15), 1949–1955.PubMedCrossRefGoogle Scholar
  123. 123.
    Ruffell, B., et al. (2012). Leukocyte composition of human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2796–2801.PubMedCrossRefGoogle Scholar
  124. 124.
    Acharyya, S., et al. (2011). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150(1), 165–178.CrossRefGoogle Scholar
  125. 125.
    Iyengar, P., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. The Journal of Clinical Investigation, 115(5), 1163–1176.PubMedGoogle Scholar
  126. 126.
    Iyengar, P., et al. (2003). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene, 22(41), 6408–6423.PubMedCrossRefGoogle Scholar
  127. 127.
    Finley, D. S., et al. (2009). Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. Journal of Urology, 182(4), 1621–1627.PubMedCrossRefGoogle Scholar
  128. 128.
    Yu, J. M., et al. (2008). Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells and Development, 17(3), 463–473.PubMedCrossRefGoogle Scholar
  129. 129.
    Walter, M., et al. (2009). Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene, 28(30), 2745–2755.PubMedCrossRefGoogle Scholar
  130. 130.
    Welte, G., et al. (2012). Interleukin-8 derived from local tissue-resident stromal cells promotes tumor cell invasion. Molecular Carcinogenesis, 51, 861–868.Google Scholar
  131. 131.
    Pinilla, S., et al. (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Letters, 284(1), 80–85.PubMedCrossRefGoogle Scholar
  132. 132.
    Devarajan, E., et al. (2011). Epithelial–mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. International Journal of Cancer, 131(5), 1023–1031.CrossRefGoogle Scholar
  133. 133.
    Muehlberg, F. L., et al. (2009). Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis, 30(4), 589–597.PubMedCrossRefGoogle Scholar
  134. 134.
    Bochet, L., et al. (2011). Cancer-associated adipocytes promotes breast tumor radioresistance. Biochemical and Biophysical Research Communications, 411(1), 102–106.PubMedCrossRefGoogle Scholar
  135. 135.
    Ligibel, J. (2011). Obesity and breast cancer. Oncology (Williston Park, N.Y.), 25(11), 994–1000.Google Scholar
  136. 136.
    Dirat, B., et al. (2010). Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocrine Development, 19, 45–52.PubMedCrossRefGoogle Scholar
  137. 137.
    Harris, R. E., et al. (2009). Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology, 17(2), 55–67.PubMedCrossRefGoogle Scholar
  138. 138.
    Dougall, W. C., et al. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326–335.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Shanghai Ruijin Hospital, Comprehensive Breast Health CenterShanghaiChina
  2. 2.Department of UrologyUniversity of MichiganAnn ArborUSA
  3. 3.University of Colorado Comprehensive Cancer CenterAuroraUSA
  4. 4.Department of Biochemistry and Molecular & Cell BiologyShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations